Figure 1From: A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants Chemical structures of approved NNRTIs rilpivirine (1), etravirine (2), nevirapine (3), efavirenz (4) and delaviridine (5). Back to article page